Manufacturing a global revolution in gene therapy
by MARK ANGELINO, PhD, FOUNDER & CHIEF OPERATING OFFICER and GEOFF MCDONOUGH, MD, PRESIDENT & CHIEF EXECUTIVE OFFICER In the early 1940s, Pfizer executive John Smith wrote of the revolutionary drug penicillin: “[T]he yields are low, the isolation is difficult, the extraction is murder, the purification invites disaster, and the assay is unsatisfactory.”1 Read More
Bringing the light of gene therapy to more patients
by GEOFF MCDONOUGH, MD, PRESIDENT & CHIEF EXECUTIVE OFFICER
and DOUG KERR, MD, PhD, MBA, CHIEF DEVELOPMENT OFFICER Thomas Edison’s first lightbulb in 1879 sparked a revolution. Using electricity that was passed through a platinum filament, his glass bulb required less power than the existing lamps of the day.
But it also lasted only a few hours before burning out. Read More
Genetic diseases steal too many kids' futures. It doesn’t have to be this way.
by GEOFF MCDONOUGH, MD, President & Chief Executive Officer and DOUG KERR, MD, PhD, MBA, Chief Development Officer This piece was originally published on WBUR’s Cognoscenti.
I want to live in a world where children have never heard of hemophilia or cystic fibrosis, because we have all but eradicated those diseases.
This isn’t a dream. The biotech industry is beginning Read More
Right from the beginning: returning to the origins of the orphan drug movement
by GEOFF MCDONOUGH, MD, PRESIDENT & CHIEF EXECUTIVE OFFICER This article was originally published as part of the From The Trenches feature of LifeSciVC.
Our industry stands at the beginning of the most significant opportunity to impact genetic and metabolic disease we have ever encountered – the ability to decisively intervene in the perinatal period with therapies capable of lifelong Read More